北京天坛生物制品股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600161 证券简称：天坛生物 公告编号：2025-025 每股分配比例： A 股每股现金红利0.1元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 27 日的2024年年度股东大会审议通过。 二、分配方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公 司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 四、分配实施办法 1.实施办法 公司所有股东为无限售条件流通股股东。除公司自行发放对 ...

Core Viewpoint - The control of blood product company Palin Bio (000403.SZ) has been transferred to China National Pharmaceutical Group (Sinopharm), which may lead to the integration of Palin Bio and Tian Tan Bio (600161.SH), potentially reshaping the competitive landscape in the blood product industry [1][5][9]. Group 1: Company Control and Financials - On June 10, Palin Bio announced that its controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Biotechnology Co., Ltd. [1] - The transaction is valued at 38.44 billion yuan, with a share price of 24.96 yuan, representing a 47% premium over the closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings ratio for this transaction is close to 32 times, based on a projected net profit of 7.45 billion yuan for 2024 [3][4]. Group 2: Industry Competition and Market Position - The integration of Tian Tan Bio and Palin Bio could lead to a combined revenue of approximately 86.87 billion yuan, surpassing Shanghai Lai Shi's (002252.SZ) projected revenue of 81.76 billion yuan for 2024 [7][15]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations and have a total plasma collection volume of 4,181 tons, significantly increasing market share to nearly 30% [7][16]. - The blood product industry is experiencing consolidation due to limited new entrants since 2001, with companies increasingly acquiring others to expand market share [16][17]. Group 3: Challenges and Future Outlook - The integration process may face challenges, particularly regarding the internal conflicts within Palin Bio, especially with its second-largest shareholder, Harbin Tongzhi Cheng Technology Development Co., Ltd. [10][11][14]. - The future of the blood product industry may depend on how effectively China National Pharmaceutical Group can manage these internal dynamics while pursuing further consolidation [9][14]. - The industry is also exploring innovative solutions to reduce reliance on human plasma, with several companies making progress in developing recombinant products [21][22].

Core Viewpoint - The acquisition of a controlling stake in Pailin Biological by China National Pharmaceutical Group signifies a significant shift in ownership and control within the blood products industry in China, with implications for market competition and consolidation strategies [2][3]. Group 1: Acquisition Details - Pailin Biological's controlling shareholder, Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Pharmaceutical for a total cash consideration of 3.844 billion yuan [1][3]. - The transaction values Pailin Biological at 24.96 yuan per share, representing a 47% premium over its closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings (P/E) ratio for this transaction is approximately 32 times, based on Pailin's projected net profit of 745 million yuan for 2024 [3]. Group 2: Industry Context - The valuation of Pailin Biological is notably higher than that of several other A-share blood product companies, which have P/E ratios around 25 times, with only Boya Bio reaching 36 times [4]. - The scarcity of blood products in China, due to regulatory restrictions on new production facilities since 2001, underpins the rationale for China National Pharmaceutical's substantial investment [5]. Group 3: Competitive Landscape - Following the acquisition, Tian Tan Biological, another player in the blood products sector, will face increased competition as both companies operate in the same industry [6]. - There are expectations that China National Pharmaceutical may integrate Pailin Biological into Tian Tan Biological, enhancing operational efficiency and market share [8]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations, with a total collection volume exceeding 4,000 tons, significantly outpacing competitors like Shanghai Raist and Hualan Biological [8][9].

Core Viewpoint - The announcement reveals that the controlling shareholder of Palin Bio (000403.SZ), Shengbang Yinghao, has signed a framework agreement with China National Biotechnology Group (China Bio) to transfer 21.03% of its shares, which will result in a change of control to China Bio, with the actual controller shifting from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group [1][4]. Group 1: Transaction Details - China Bio will acquire the shares from Shengbang Yinghao through a cash transaction, with the price set at the principal amount of 3.844 billion yuan plus interest calculated at an annual simple interest rate of 9% from March 20, 2023, until the signing of the transaction documents [4]. - To ensure fair information disclosure and protect investor interests, Palin Bio's stock was suspended from trading starting June 6, 2025, with an expected suspension period of no more than two trading days [4]. Group 2: Company Background - Palin Bio specializes in the research, development, production, and sales of blood products, using healthy human plasma or specifically immunized human plasma as raw materials, which are critical strategic reserves and emergency medications for major diseases [4]. - China Bio, a core biopharmaceutical enterprise under China National Pharmaceutical Group, operates in blood products, vaccines, and medical diagnostics, holding a significant position in the domestic blood products market [4][5]. Group 3: Strategic Implications - If the acquisition is completed, China Bio may achieve synergy between its platforms, Tian Tan Bio and Palin Bio, further consolidating its advantages in the blood products industry [5]. - The previous change in control of Palin Bio occurred less than two years ago when Shengbang Yinghao took over from Hangzhou Zhemin Investment, which led to internal disputes and board changes, culminating in a resolution in December 2023 [5]. Group 4: Financial Performance - In the first quarter of 2025, Palin Bio reported revenue of 375 million yuan, a year-on-year decline of 14%, and a net profit attributable to shareholders of 89 million yuan, down 26.95% year-on-year, primarily due to production capacity expansion halts at its subsidiary [5].

特此公告。 证券代码：600161 证券简称：天坛生物 公告编号：2025-024 北京天坛生物制品股份有限公司 关于完成工商变更登记并取得换发《营业执照》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）于2025年5月27日召开 2024年年度股东大会，审议通过《关于修订<公司章程>的议案》、《关于增补董事 的议案》和《关于撤销监事会并废止<监事会议事规则>的议案》。同日，公司召开 第九届董事会第二十一次会议，审议通过《关于变更法定代表人的议案》和《关于 聘任董事会秘书的议案》。 近日，公司已完成上述审议通过事项涉及的《公司章程》、法定代表人、董事、 监事、高级管理人员等工商变更登记工作，并取得北京经济技术开发区市场监督管 理局换发的《营业执照》，《营业执照》信息中的公司法定代表人变更为何彦林先 生，《营业执照》其他信息不变。 北京天坛生物制品股份有限公司 2025 年 5 月 29 日 ...

证券代码：600161 证券简称：天坛生物 公告编号：2025-023 北京天坛生物制品股份有限公司 关于向下属企业提供委托贷款暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1.北京天坛生物制品股份有限公司（以下简称"公司"）为满足下属国药集团 昆明血液制品有限公司（以下简称"昆明血制"）、国药集团贵州生物制药有限公 司（以下简称"贵州血制"）、国药集团兰州生物制药有限公司（以下简称"兰州 血制"）、国药集团上海血液制品有限公司（以下简称"上海血制"）业务发展资 金需求，本着节约财务成本，降低财务费用的原则，拟以自有资金通过国药集团财 务有限公司（以下简称"国药财务"）向上述企业提供合计不超过39,700万元委托 贷款，期限1年，贷款利率参照中国人民银行一年期贷款市场报价利率（LPR）执行， 手续费率为万分之零点五。 2.公司与国药财务受同一实际控制人中国医药集团有限公司（以下简称"国药 集团"）控制，根据《上海证券交易所股票上市规则》，上述交易构成关联交易。但 不构成《上市公司重大资产重组 ...

证券代码：600161 证券简称：天坛生物 公告编号：2025-021 北京天坛生物制品股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025 年 5 月 27 日 （二）股东大会召开的地点：北京市朝阳区双桥路乙 2 号院会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 695 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,018,747,977 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 51.52 | | 总数的比例（%） | | （四）表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，董事长杨汇川先生主持，公司部分董事、监事、高级 管理人员出席了会议，会议采用现场投票与网络投票相结合的方式对提案进行表决， 符 ...

北京市嘉源律师事务所 关于北京天坛生物制品股份有限公司 2024 年年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 EUT = 3 PT YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI ·深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:北京天坛生物制品股份有限公司 北京市嘉源律师事务所 关于北京天坛生物制品股份有限公司 2024 年年度股东大会的法律意见书 嘉源(2025)-04-377 敬启者: 北京市嘉源律师事务所(以下简称"本所")接受北京天坛生物制品股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》等现行有效的法律、行政法规、部门规 章、规范性文件(以下简称"法律法规")以及《北京天坛生物制品股份有限公 司章程》(以下简称"《公司章程》")的有关规定,指派本所律师对公司 2024年 年度股东大会(以下简称"本次股东大会")进行见证,并依法出具本法律意见 书。 为出具本法律意见书,本所指派律师现场 ...

北京天坛生物制品股份有限公司 第九届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600161 证券简称：天坛生物 公告编号：2025-022 北京天坛生物制品股份有限公司（以下简称"公司"）第九届董事会第二十 一次会议于 2025 年 5 月 16 日以电子方式发出会议通知，于 2025 年 5 月 27 日以 现场与视频结合方式在北京市朝阳区双桥路乙 2 号院办公楼三层会议室召开。会 议由董事长杨汇川先生主持，会议应到董事九人，实到董事九人。会议出席人数 符合《公司法》及《公司章程》规定的有效人数，会议按预定程序审议了议程中 全部议案。会议做出决议如下： 一、审议通过《关于变更法定代表人的议案》 同意将公司法定代表人变更为何彦林先生。 表决结果：9 票同意，0 票反对，0 票弃权。 五、审议通过《关于向下属企业提供委托贷款暨关联交易的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 二、审议通过《关于补选董事会审计与风险管理委员会委员的议案》 同意补选汪祺先生为公司第九届董事 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [3] Core Views - The company achieved a revenue of 60.32 billion yuan and a net profit of 15.49 billion yuan in 2024, reflecting year-on-year growth of 16.44% and 39.58% respectively [1][7] - The company is expected to experience a slowdown in profit growth in 2025, with a projected net profit of 15.91 billion yuan [7] - The company has completed three new production capacities, which are anticipated to gradually release supply [7] Financial Performance - In 2024, the company's core products, human albumin and intravenous immunoglobulin, generated revenues of 25.10 billion yuan and 27.58 billion yuan, with year-on-year growth of 11.70% and 18.90% respectively [7] - The company’s total revenue is projected to grow from 51.80 billion yuan in 2023 to 72.38 billion yuan in 2025, representing a compound annual growth rate of approximately 20% [2][9] - The net profit is expected to increase from 11.10 billion yuan in 2023 to 15.91 billion yuan in 2025, with a growth rate of 3% [2][10] Production and Supply Chain - The company has expanded its plasma collection stations to a total of 107, with 85 currently operational, collecting 2,781 tons of plasma, a year-on-year increase of 15.15% [7] - The company has acquired a new blood product production enterprise and five additional operational plasma collection stations, increasing annual plasma collection by over 100 tons [7] Future Outlook - The company aims for a revenue target of 74.40 billion yuan and a net profit of 21.96 billion yuan for 2025 [7] - The report anticipates that the new production capacities will drive performance growth in the coming years [7]